Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

for the application of its recombinant human enzyme, rHuPH20, to three pre-defined biologic targets exclusive to Roche. In December 2008, Roche selected a fourth biologic target followed by selection of a fifth target in June 2009 and has the option to exclusively develop and commercialize rHuPH20 with an additional eight potential targets. In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Pending the successful achievement of a series of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on future product sales.  

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze™ technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to hist
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 31, 2011 The Procter & Gamble Company (NYSE: ... joined its U.S. Sustainability Expert Advisory Panel (SEAP). The new ... Senior Manager, Clinton Global Initiative Dr. Howard Frumkin – ... Washington Terry Tamminen – Former Secretary, California Environmental Protection ...
... May 31, 2011 HeartSine Technologies, Inc, a ... its system warranty period to an exclusive 10 years on ... Public Access Defibrillator (PAD) for the ... currently is the fastest growing AED. The life of its ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3HeartSine® Increases AED System Warranty to Longest in the Industry 2
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... at the University of California, San Diego School of ... who have suffered a recent major loss are more ... adults. , The study is published in this month,s ... . , Because compassionate behaviors are associated with better ... offer insights into ways to improve the outcomes of ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... multinational corporation headquartered in Japan and the world,s ... of Toray Water Technology Laboratory (TWTL) in Singapore ... technologies. Nanyang Technological University (NTU),s Nanyang Environment and ... choice partner for its research activities in Singapore. ...
... Association (AUA) Foundation announced that Jennifer Dodson, MD, of ... AUA Foundation/NIDDK/NCI Surgeon-Scientist Award, offered by the AUA Foundation, ... Diseases (NIDDK) and the National Cancer Institute (NCI). ... have received the Surgeon-Scientist Award since the program began ...
... June 25, 2009, TIME: ... 722 12th St, NW, EVENT: ... town meeting to explain opposition to health care reform , ... on the 44th anniversary of Medicare., ...
... National Business Group on Health Recognizes HealthyQuest Program for ... 24 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that the National Business Group ... for Healthy Lifestyles Platinum Award to the company for ...
... CORTLANDT MANOR, N.Y., June 24 Polymedco, Inc. ... PATHFAST immunoassay analyzer, manufactured by Mitsubishi Chemical Medience ... of care system utilizes a chemiluminescent technology combined ... that allows this system to report highly accurate ...
... 2009) For Professor Chad Mirkin, good things come ... meter in size. Yet, as director of Northwestern University,s ... is anything but small. A prolific inventor and entrepreneur, ... of medical diagnostics and patient point-of-care and to ignite ...
Cached Medicine News:Health News:Toray to establish water treatment R&D center at NTU in Singapore 2Health News:Toray to establish water treatment R&D center at NTU in Singapore 3Health News:National Physician Summit & Petition: 'Take Back Medicine' 6/25/09 2Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 2Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 3Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 4Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 5Health News:PATHFAST(R) Rapid Whole Blood Immunoassay Analyzer from Polymedco 2Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 2Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 3Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 4
ROB-NEL Catheters (100% Latex-Free)...
Urethral Red Rubber Catheters (Latex)...
ULTRAMER Foley Catheter...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: